{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:24:35Z","timestamp":1789705475008,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejca.2023.112944","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T12:25:31Z","timestamp":1687263931000},"page":"112944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1150-0345","authenticated-orcid":false,"given":"Carmine","family":"Valenza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-9560","authenticated-orcid":false,"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1348-4548","authenticated-orcid":false,"given":"Sara","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3211-8516","authenticated-orcid":false,"given":"Caterina","family":"Sposetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boscolo Bielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7310-7824","authenticated-orcid":false,"given":"Antonio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Giarratano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-2840","authenticated-orcid":false,"given":"Diletta","family":"Favero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8950-8561","authenticated-orcid":false,"given":"Laura","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Moscetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Pistelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zambelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2375-8397","authenticated-orcid":false,"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.112944_bib1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.ejca.2023.112944_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13058-016-0709-1","article-title":"Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation","volume":"18","author":"Baert","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2023.112944_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMe0903044","article-title":"Synthetic lethality \u2014 a new direction in cancer-drug development","volume":"361","author":"Iglehart","year":"2009","journal-title":"New Engl\u00a0J\u00a0Med"},{"key":"10.1016\/j.ejca.2023.112944_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2023.112944_bib5","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.112944_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","article-title":"An overview of PARP inhibitors for the treatment of breast cancer","volume":"16","author":"Cortesi","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2023.112944_bib7","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/s41416-022-02003-1","article-title":"Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1\/2 mutations","volume":"127","author":"Jacot","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2023.112944_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"New Engl\u00a0J\u00a0Med"},{"key":"10.1016\/j.ejca.2023.112944_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"New Engl\u00a0J\u00a0Med"},{"key":"10.1016\/j.ejca.2023.112944_bib10","first-page":"1526","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112944_bib11","first-page":"558","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112944_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ygyno.2022.01.015","article-title":"Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer","volume":"164","author":"Colombo","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2023.112944_bib13","first-page":"1021","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112944_bib14","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P4-01-08","article-title":"Abstract P4-01-08: efficacy of PARP inhibitors in patients with BRCA1\/2-related breast cancer with prior platinum exposure: a systematic review and meta-analysis","volume":"83","author":"Marinho","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2023.112944_bib15","first-page":"389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112944_bib16","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1002\/cncr.30830","article-title":"Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?","volume":"123","author":"Tomao","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.112944_bib17","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41416-022-02108-7","volume":"128","author":"Colombo","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2023.112944_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","article-title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial","volume":"23","author":"Kristeleit","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.112944_bib19","first-page":"1410","article-title":"Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis","volume":"32","author":"Maiorano","year":"2022","journal-title":"Int\u00a0J\u00a0Gynecol\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.112944_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","article-title":"OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"184","author":"Robson","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.112944_bib21","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.112944_bib22","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.112944_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.694793","article-title":"Analysis of adaptive olaparib resistance effects on cisplatin sensitivity in triple negative breast cancer cells","volume":"11","author":"Gajan","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2023.112944_bib24","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/cancers12061607","article-title":"Overcoming platinum and PARP-Inhibitor resistance in ovarian cancer","volume":"12","author":"McMullen","year":"2020","journal-title":"Cancers ((Basel))"},{"key":"10.1016\/j.ejca.2023.112944_bib25","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science ((1979))"},{"key":"10.1016\/j.ejca.2023.112944_bib26","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","article-title":"Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance","volume":"10","author":"Pettitt","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2023.112944_bib27","first-page":"590","article-title":"Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1\/2-mutant metastatic breast cancer","volume":"31","author":"Waks","year":"2020","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112944_bib28","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-6094","article-title":"Abstract 6094: longitudinal analysis of PARP inhibitor and platinum resistance in BRCA1\/2m breast cancer using liquid biopsy","volume":"83","author":"Harvey-Jones","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2023.112944_bib29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2023.112944_bib30","first-page":"1324","article-title":"Talazoparib exposure-efficacy analysis in patients with advanced breast cancer and germline BRCA1\/2 mutations in the EMBRACA trial","volume":"60","author":"Yu","year":"2020","journal-title":"J\u00a0Clin\u00a0Pharmacol"},{"key":"10.1016\/j.ejca.2023.112944_bib31","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-CT007","article-title":"Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations","volume":"82","author":"Yap","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2023.112944_bib32","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","article-title":"A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:41Z","timestamp":1760733701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923002964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":32,"alternative-id":["S0959804923002964"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112944","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112944"}}